Human lung tumor growth established in the lung and subcutaneous tissue of mice with severe combined immunodeficiency.
Human lung tumor growth established in the lung and subcutaneous tissue of mice with severe combined immunodeficiency.
复制标题
DOI：
--
复制
发表时间：
1987-05
期刊：
影响因子：
11.2
通讯作者：
S. Reddy;D. Piccione;H. Takita;R. Bankert
中科院分区：
文献类型：
--
作者：
S. Reddy;D. Piccione;H. Takita;R. Bankert
我们在这里报告，小鼠突变体（C.B-17 scid），缺乏功能性B-和T-淋巴细胞，可用于传播人肺肿瘤。异源移植瘤细胞在皮下产生可触及的肿瘤细胞。在100%的小鼠中，18天后皮下接种肿瘤。大于4 × 10（6）个细胞。所有肿瘤均进行性生长，无消退迹象。一部分scid小鼠静脉注射了人肺肿瘤细胞，在接种肿瘤细胞15周后，肺内出现了多个肿瘤结节。通过核型分析显示肿瘤结节是人类细胞，并且肿瘤结节的组织病理学显示与原始肿瘤一致的生长模式。研究中使用的人肺肿瘤表达了一种Mr 160，000的细胞表面糖蛋白，该糖蛋白已被证明存在于大部分人肺肿瘤和肿瘤细胞系中。使用对Mr 160，000糖蛋白具有特异性的单克隆抗体来证明该肿瘤相关抗原由皮下细胞稳定表达。肿瘤和肺肿瘤结节。具有这种严重联合免疫缺陷的突变小鼠代表了一种新的可行的模型，用于传播人类肿瘤和评估新型药物递送方案在治疗人类癌症中的功效。
We report here that a mouse mutant (C.B-17 scid) which lacks functional B- and T-lymphocytes can be used to propagate a human lung tumor. The heterotransplanted tumor cells generated palpable s.c. tumors by 18 days in 100% of the mice inoculated s.c. with greater than 4 X 10(6) cells. All tumors grew progressively with no sign of regression. A portion of the scid mice given injections i.v. of the human lung tumor cells developed multiple tumor nodules in the lung by 15 weeks after the inoculation of tumor cells. The tumor nodules were shown by karyotype analysis to be human cells, and the histopathology of the tumor nodules revealed a pattern of growth that was consistent with that of the original tumor. The human lung tumor used in the study expresses an Mr 160,000 cell surface glycoprotein that has been shown to occur on a large proportion of human lung tumors and tumor cell lines. A monoclonal antibody specific for Mr 160,000 glycoprotein was used to demonstrate that this tumor-associated antigen is stably expressed by the s.c. tumors and the lung tumor nodules in the scid mice. The mutant mice with this severe combined immunodeficiency represent a new and viable model for propagating human tumors and for evaluating the efficacy of novel drug delivery protocols in the treatment of human cancer.